Adverse Events Associated With PCSK9 Inhibitors: A Real-World Experience
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Adverse Events Associated With PCSK9 Inhibitors: A Real-World Experience
Authors
Keywords
-
Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2018-07-28
DOI
10.1002/cpt.1193
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Lipid-lowering therapy with PCSK9-inhibitors in the management of cardiovascular high-risk patients: Effectiveness, therapy adherence and safety in a real world cohort
- (2018) Michael Saborowski et al. Cardiology Journal
- No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized Phase 2 and 3 controlled trials: a meta-analysis of individual patient data
- (2017) Philip D Harvey et al. EUROPEAN HEART JOURNAL
- 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia
- (2017) Ulf Landmesser et al. EUROPEAN HEART JOURNAL
- Pro-protein subtilisin kexin-9 (PCSK9) inhibition in practice: lipid clinic experience in 2 contrasting UK centres
- (2017) Monika Kohli et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Proprotein convertase subtilisin/kexin 9 inhibition in patients with familial hypercholesterolemia: Initial clinical experience
- (2017) Annette M.H. Galema-Boers et al. Journal of Clinical Lipidology
- Safety of Very Low Low-Density Lipoprotein Cholesterol Levels With Alirocumab
- (2017) Jennifer G. Robinson et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial
- (2017) Robert P Giugliano et al. LANCET
- Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, a post-commercialization study
- (2017) Joshua Choi et al. Lipids in Health and Disease
- Cognitive Function in a Randomized Trial of Evolocumab
- (2017) Robert P. Giugliano et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- (2017) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
- (2017) Kausik K. Ray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Increased Risk of Adverse Neurocognitive Outcomes With Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors
- (2017) Abdur Rahman Khan et al. Circulation-Cardiovascular Quality and Outcomes
- Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized Controlled Trials
- (2017) Aris Karatasakis et al. Journal of the American Heart Association
- Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers
- (2017) Alejandro Arrieta et al. JAMA Cardiology
- Safety of Alirocumab (A PCSK9 Monoclonal Antibody) from 14 Randomized Trials
- (2016) Peter H. Jones et al. AMERICAN JOURNAL OF CARDIOLOGY
- Prediction of cardiovascular events with levels of proprotein convertase subtilisin/kexin type 9: A systematic review and meta-analysis
- (2016) Charalambos Vlachopoulos et al. ATHEROSCLEROSIS
- PCSK9 inhibition as an emerging lipid lowering therapy: Unanswered questions
- (2016) Lοukianos S. Rallidis et al. Hellenic Journal of Cardiology
- Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials
- (2015) Xin-Lin Zhang et al. BMC Medicine
- Effects of Evolocumab on Vitamin E and Steroid Hormone LevelsNovelty and Significance
- (2015) Dirk J. Blom et al. CIRCULATION RESEARCH
- The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis
- (2015) Michael J. Lipinski et al. EUROPEAN HEART JOURNAL
- Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
- (2015) Jennifer G. Robinson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
- (2015) Christopher P. Cannon et al. NEW ENGLAND JOURNAL OF MEDICINE
- The safety of therapeutic monoclonal antibodies: Implications for cardiovascular disease and targeting the PCSK9 pathway
- (2013) A.L. Catapano et al. ATHEROSCLEROSIS
- Immunotoxicity of monoclonal antibodies
- (2010) Jacques Descotes mAbs
- Beyond the Randomized Clinical Trial
- (2008) Brahmajee K. Nallamothu et al. CIRCULATION
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More